Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | CDC7 | O00311 | 4/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227206 | 1.00 | HRH3 (0.58) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31247170 | 0.87 | HRH3 (0.65) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31227772 | 0.87 | HRH3 (0.65) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31227534 | 0.87 | HRH3 (0.65) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31246523 | 0.84 | HRH3 (0.57) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31227779 | 0.84 | HRH3 (0.57) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL31227587 | 0.84 | HRH3 (0.57) | HRH3HRH4ROCK1CDK2CDK1 | |
| SCHEMBL13018663 | 0.84 | HRH3 (0.70) | HRH3HRH4ROCK1CDK2CDC7 | |
| SCHEMBL17626635 | 0.82 | HRH3 (0.60) | HRH3HRH4ROCK1CDK2CDC7 | |
| SCHEMBL17626690 | 0.82 | HRH3 (0.63) | HRH3HRH4ROCK1CDK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524392-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC | 2014-01-22 | — | — | CN | disclosed |
| CN-101365676-B | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC | 2013-09-11 | — | — | CN | disclosed |
| CN-101605540-A | Methods of using MEK inhibitors | EXELIXIS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| CN-101365676-A | Azetidines as mek inhibitors for the treatment of proliferative diseases | EXELIXIS INC (US) | 2009-02-11 | — | — | CN | disclosed |